Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the effectiveness and safety of a minimally invasive surgical procedure with ACT (Adjustable Continence Therapy) balloons implantation for the treatment of urinary incontinence in children with bladder exstrophy or isolated epispadias.
The ACT therapy consists of two small adjustable silicone balloons connected with a tubing to a port, surgically placed around the bladder neck, one on each side of the urethra.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Study Arm 1 | Experimental | Children with bladder exstrophy or isolated epispadias |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ACT | Device | Implantation of ACT balloon, Uromedica (Irvine, CA, USA) periurethrally at the bladder neck. The ACT system is a permanent implant designed for the correction of incontinence in patients. |
| Measure | Description | Time Frame |
|---|---|---|
| Evaluation of the clinical impact of ACT balloon on urinary continence with pad weight | Therapeutic success will be based on whether patients demonstrate at least a 50% reduction in 24 hour Pad weight at 6, 12 and 24 months follow-up compared to the pad weight results at baseline. | 24 months |
| Measure | Description | Time Frame |
|---|---|---|
| Number of pads per day (voiding diary) | Change of number of peds changed per day from baseline to 6, 12 and 24 months (the best : 0 pads changed a day). | 6, 12 and 24 months |
| Number of incontinence episodes per day (voiding diary) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Alice FAURE, MD | Contact | 04.91.96.81.41 | alice.faure@ap-hm.fr | |
| Claire MORANDO | Contact | 04 91 38 21 83 | claire.morando@ap-hm.fr |
| Name | Affiliation | Role |
|---|---|---|
| Emilie GARRIDO-PRADALIE | Assistance Publique Hôpitaux de Marseille | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Assistance Publique Hopitaux de Marseille | Recruiting | Marseille | PACA | 13354 | France |
Not provided
| ID | Term |
|---|---|
| D001746 | Bladder Exstrophy |
| ID | Term |
|---|---|
| D014564 | Urogenital Abnormalities |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Change in number of incontinence episodes per day from baseline to 6, 12 and 24 months (the best : 0)
| 6, 12 and 24 months |
| PIN-Q questionnaire | Change on validated incontinence quality of life questionnaire from baseline to 6, 12 and 24 months | 6, 12 and 24 months |
| Incidence of urethral stricture and device erosion after ACT implantation | Cumulative incidence of ACT related clinically relevant urethral structure and device erosions (the best : 0) | 6, 12 and 24 months |
| D001745 | Urinary Bladder Diseases |
| D014570 | Urologic Diseases |
| D052801 | Male Urogenital Diseases |
| D000013 | Congenital Abnormalities |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |